WO2021164741A1 - Composé de bisamide de phényle - Google Patents

Composé de bisamide de phényle Download PDF

Info

Publication number
WO2021164741A1
WO2021164741A1 PCT/CN2021/076912 CN2021076912W WO2021164741A1 WO 2021164741 A1 WO2021164741 A1 WO 2021164741A1 CN 2021076912 W CN2021076912 W CN 2021076912W WO 2021164741 A1 WO2021164741 A1 WO 2021164741A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
acid
present
Prior art date
Application number
PCT/CN2021/076912
Other languages
English (en)
Chinese (zh)
Inventor
张杨
黄荣新
孙继奎
李婕
伍文韬
黎健
陈曙辉
Original Assignee
南京明德新药研发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京明德新药研发有限公司 filed Critical 南京明德新药研发有限公司
Publication of WO2021164741A1 publication Critical patent/WO2021164741A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a class of phenyl bisamide compounds, in particular to a compound represented by formula (P) or a pharmaceutically acceptable salt thereof.
  • the RET gene is a proto-oncogene that rearranges during the transfection process, hence its name. This gene encodes a cell membrane receptor tyrosine kinase. When the growth factor binds to the extracellular region of RET, it will Trigger a series of chain chemical reactions within the cell, according to the signal received by the receptor, cause the cell to divide and mature, and then play a corresponding function on the development of the organ and the homeostasis of the tissue. RET protein plays an important role in the development of several nerves (including the intestine and autonomic nervous system).
  • RET plays a key role in regulating the development of sympathetic, parasympathetic, motor and sensory nerves in the enteric nervous system (ENS).
  • the RET gene knockout mice lack enteric neurons and have other neurological abnormalities, which means that a functional RET kinase protein product is required during growth.
  • Hirschsprung patients with loss-of-function RET mutations and lack of normal colonic nerve distribution can cause colonic obstruction. Therefore, inhibiting RET in the enteric nervous system is a new treatment strategy for normalizing nerve function and alleviating the symptoms of irritable bowel syndrome (IBS) patients.
  • IBS irritable bowel syndrome
  • GSK3179106 is a RET inhibitor of the pyridone class and is currently in phase I clinical study.
  • the present invention aims to develop a class of quinoline derivatives as RET inhibitors for the treatment of tumors or intestinal diseases related to abnormal activation of RET.
  • R 1 and R 2 are each independently selected from H, F, Cl, Br, I, OH, NH 2, CN, C 1-3 alkyl group and a C 1-3 alkoxy group, a C 1- 3 alkyl and a C 1-3 alkoxy group optionally substituted with 1, 2 or 3 R a;
  • Each R 3 is independently selected from H, F, Cl, Br and I;
  • R 4 is selected from H, F, Cl, Br and I;
  • R 5 is selected from H, F, Cl, Br, I and C 1-3 alkyl, the C 1-3 alkyl is optionally substituted with 1, 2 or 3 R b ;
  • R 6 is selected from H, F, Cl, Br, I and C 1-3 alkyl, the C 1-3 alkyl is optionally substituted with 1, 2 or 3 R c ;
  • Each R a is independently selected from H, F, Cl, Br and I;
  • Each R b is independently selected from H, F, Cl, Br and I;
  • Each R c is independently selected from H, F, Cl, Br, I and C 1-3 alkylamino group, said C 1-3 alkylamino group is optionally substituted by 1, 2 or 3 R;
  • Each R is independently selected from H, F, Cl, Br and I;
  • n 0, 1, 2 and 3.
  • the R 1 and R 2 are each independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2.
  • OCH 3 , OCH 2 CH 3 and OCH(CH 3 ) 2 are optional 1, 2 or 3 substituents R a, the other variables are as defined in the present invention.
  • the R 1 and R 2 are each independently selected from OCH 3 , and other variables are as defined in the present invention.
  • the R 5 is selected from H, F, Cl, Br, I, CH 3 , CH 2 CH 3 and CH(CH 3 ) 2 , the CH 3 , CH 2 CH 3 and CH (CH 3 ) 2 is optionally substituted with 1, 2 or 3 R b , and other variables are as defined in the present invention.
  • the R 5 is selected from CF 3 , and other variables are as defined in the present invention.
  • the R 6 is selected from H, F, Cl, Br, I, CH 3 , CH 2 CH 3 and CH(CH 3 ) 2 , the CH 3 , CH 2 CH 3 and CH (CH 3 ) 2 is optionally substituted with 1, 2 or 3 R c , and other variables are as defined in the present invention.
  • the R 6 is selected from Other variables are as defined in the present invention.
  • the compound or a pharmaceutically acceptable salt thereof is selected from,
  • R 1 , R 2 and R 6 are as defined in the present invention.
  • the present invention also provides a compound represented by the following formula or a pharmaceutically acceptable salt thereof,
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
  • the present invention also provides the application of the above-mentioned compound or its pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition in the preparation of a medicine for the treatment of RET disease.
  • the compound of the present invention has a good inhibitory effect on wild-type and V804M mutant RET kinase. It has good one-phase metabolic stability and good drug interaction safety. It is not absorbed into the blood after oral administration, avoiding the toxic side effects of drugs.
  • pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues. , Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to a salt of the compound of the present invention, which is prepared from a compound with specific substituents discovered in the present invention and a relatively non-toxic acid or base.
  • a base addition salt can be obtained by contacting the compound with a sufficient amount of base in a pure solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salt or similar salts.
  • the acid addition salt can be obtained by contacting the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogen carbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, the organic acid includes, for example, acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid; also include salts of amino acids (such as arginine, etc.) , And salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and
  • the pharmaceutically acceptable salt of the present invention can be synthesized from the parent compound containing acid or base by conventional chemical methods. In general, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or organic solvent or a mixture of both.
  • the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers Isomers, (D)-isomers, (L)-isomers, and their racemic mixtures and other mixtures, such as enantiomers or diastereomer-enriched mixtures, all of these mixtures belong to this Within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All these isomers and their mixtures are included in the scope of the present invention.
  • enantiomer or “optical isomer” refers to stereoisomers that are mirror images of each other.
  • cis-trans isomer or “geometric isomer” is caused by the inability to rotate freely because of double bonds or single bonds of ring-forming carbon atoms.
  • diastereomer refers to a stereoisomer in which the molecule has two or more chiral centers and the relationship between the molecules is non-mirror-image relationship.
  • wedge-shaped solid line keys And wedge-shaped dashed key Represents the absolute configuration of a three-dimensional center, with a straight solid line key And straight dashed key Indicates the relative configuration of the three-dimensional center, using wavy lines Represents a wedge-shaped solid line key Or wedge-shaped dashed key Or use wavy lines Represents a straight solid line key And straight dashed key
  • the following formula (A) means that the compound exists as a single isomer of formula (A-1) or formula (A-2) or as two isomers of formula (A-1) and formula (A-2)
  • the following formula (B) means that the compound exists in the form of a single isomer of formula (B-1) or formula (B-2) or in the form of two of formula (B-1) and formula (B-2) A mixture of isomers exists.
  • the following formula (C) represents that the compound exists as a single isomer of formula (C-1) or formula (C-2) or as two isomers of formula (C-1) and formula (C-2) Exist as a mixture.
  • tautomer or “tautomeric form” means that at room temperature, the isomers of different functional groups are in dynamic equilibrium and can be transformed into each other quickly. If tautomers are possible (such as in solution), the chemical equilibrium of tautomers can be reached.
  • proton tautomer also called prototropic tautomer
  • proton migration such as keto-enol isomerization and imine-ene Amine isomerization.
  • Valence isomers include some recombination of bonding electrons to carry out mutual transformations.
  • keto-enol tautomerization is the tautomerism between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.
  • the term “enriched in one isomer”, “enriched in isomers”, “enriched in one enantiomer” or “enriched in enantiomers” refers to one of the isomers or pairs of
  • the content of the enantiomer is less than 100%, and the content of the isomer or enantiomer is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or 96% or greater, or 97% or greater, or 98% or greater, or 99% or greater, or 99.5% or greater, or 99.6% or greater, or 99.7% or greater, or 99.8% or greater, or greater than or equal 99.9%.
  • the term “isomer excess” or “enantiomeric excess” refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90%, and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80% .
  • optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If you want to obtain an enantiomer of a compound of the present invention, it can be prepared by asymmetric synthesis or derivatization with chiral auxiliary agents, in which the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide pure The desired enantiomer.
  • the molecule when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), it forms a diastereomeric salt with an appropriate optically active acid or base, and then passes through a conventional method known in the art The diastereoisomers are resolved, and then the pure enantiomers are recovered.
  • the separation of enantiomers and diastereomers is usually accomplished through the use of chromatography, which uses a chiral stationary phase and is optionally combined with chemical derivatization (for example, the formation of amino groups from amines). Formate).
  • the compound of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms constituting the compound.
  • compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I), or C-14 ( 14 C).
  • deuterium can be substituted for hydrogen to form deuterated drugs.
  • the bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon.
  • deuterated drugs can reduce toxic side effects and increase drug stability. , Enhance the efficacy, extend the biological half-life of drugs and other advantages.
  • substituted means that any one or more hydrogen atoms on a specific atom are replaced by a substituent.
  • the substituent may include deuterium and hydrogen variants, as long as the valence of the specific atom is normal and the compound after substitution Is stable.
  • Oxygen substitution does not occur on aromatic groups.
  • optionally substituted means that it can be substituted or unsubstituted. Unless otherwise specified, the type and number of substituents can be arbitrary on the basis that they can be chemically realized.
  • any variable such as R
  • its definition in each case is independent.
  • the group can optionally be substituted with up to two Rs, and R has independent options in each case.
  • combinations of substituents and/or variants thereof are only permitted if such combinations result in stable compounds.
  • linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
  • substituents When a substituent is vacant, it means that the substituent is absent. For example, when X in A-X is vacant, it means that the structure is actually A.
  • substituents do not indicate which atom is connected to the substituted group, such substituents can be bonded via any atom.
  • a pyridyl group can pass through any one of the pyridine ring as a substituent. The carbon atom is attached to the substituted group.
  • the middle linking group L is -MW-, at this time -MW- can be formed by connecting ring A and ring B in the same direction as the reading order from left to right It can also be formed by connecting ring A and ring B in the opposite direction to the reading order from left to right
  • Combinations of the linking groups, substituents, and/or variants thereof are only permitted if such combinations result in stable compounds.
  • any one or more sites of the group can be connected to other groups through chemical bonds.
  • the connection method of the chemical bond is not positioned, and there is a H atom at the connectable site, when the chemical bond is connected, the number of H atoms at the site will correspondingly decrease with the number of chemical bonds connected to become the corresponding valence number ⁇ The group.
  • the chemical bond between the site and other groups can be a straight solid bond Straight dashed key Or wavy line Express.
  • the straight solid bond in -OCH 3 means that it is connected to other groups through the oxygen atom in the group;
  • the straight dashed bond in indicates that the two ends of the nitrogen atom in the group are connected to other groups;
  • the wavy line in indicates that the phenyl group is connected to other groups through the 1 and 2 carbon atoms;
  • C 1-3 alkyl is used to indicate a linear or branched saturated hydrocarbon group composed of 1 to 3 carbon atoms.
  • the C 1-3 alkyl group includes C 1-2 and C 2-3 alkyl groups, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or multivalent (such as methine) .
  • Examples of C 1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), and the like.
  • C 1-3 alkoxy refers to those alkyl groups containing 1 to 3 carbon atoms that are attached to the rest of the molecule through an oxygen atom.
  • the C 1-3 alkoxy group includes C 1-2 , C 2-3 , C 3 and C 2 alkoxy groups and the like.
  • Examples of C 1-3 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.
  • C 1-3 alkylamino refers to those alkyl groups containing 1 to 3 carbon atoms attached to the rest of the molecule through an amino group.
  • the C 1-3 alkylamino group includes C 1-2 , C 3 and C 2 alkylamino groups and the like.
  • Examples of C 1-3 alkylamino groups include, but are not limited to, -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -N(CH 3 )CH 2 CH 3 , -NHCH 2 CH 2 CH 3 ,- NHCH 2 (CH 3 ) 2 and so on.
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and those well known to those skilled in the art Equivalent alternatives, preferred implementations include but are not limited to the embodiments of the present invention.
  • the 33 P isotope-labeled kinase activity test of Reaction Biology Corp was used to determine the IC 50 value to evaluate the inhibitory ability of the test compound against human wild-type and V804M mutant RET.
  • Buffer conditions 20mM hydroxyethylpiperazine B sulfuric acid (Hepes) (pH 7.5), 10mM MgC l2, 1mM EGTA (EGTA), 0.02% polyoxyethylene dodecyl ether ( Brij35), 0.02mg/ml BSA, 0.1mM Na 3 VO 4 , 2mM dithiothreitol (DTT), 1% DMSO.
  • test compound treatment The test compound is dissolved in 100% DMSO and serially diluted with DMSO by Integra Viaflo Assist to a specific concentration.
  • Test procedure Dissolve the substrate in the newly prepared buffer, add the tested kinase to it and mix gently. Using acoustic technology (Echo 550), the DMSO solution with the test compound dissolved in the above mixed reaction solution was added and incubated at room temperature for 20 minutes. The compound concentration in the reaction solution was 3 ⁇ M, 1 ⁇ M, 0.333 ⁇ M, 0.111 ⁇ M, 0.0370 ⁇ M, 0.0123 ⁇ M, 4.12nM, 1.37nM, 0.457nM, 0.152nM. After 15 minutes of incubation, 33 P-ATP (activity 0.01 ⁇ Ci/ ⁇ l, km concentration) was added to start the reaction. After the reaction was carried out at room temperature for 120 minutes, the radioactivity was detected by the filter binding method.
  • Echo 550 acoustic technology
  • the kinase activity data is expressed by comparing the kinase activity of the test compound with that of the blank group (only containing DMSO).
  • the IC 50 value is obtained by curve fitting with Prism4 software (GraphPad). The experimental results are shown in Table 1.
  • stop solution acetonitrile solution containing 200 ng/mL tolbutamide
  • the in vitro elimination rate constant ke of the test substance and the reference substance is obtained by converting the ratio of the peak area of the sample to the internal standard in the following formula into the remaining percentage:
  • CL int(liver) CL int(mic) ⁇ mg microsomal protein/g liver weight ⁇ liver weight to weight ratio
  • mg microsomal protein/g liver weight the value is 45 for both animal and human species
  • mice and humans The parameters in mice and humans are 88 and 20g/kg, respectively.
  • MMS microsomal metabolic stability
  • H stands for human
  • M stands for mouse
  • a mixed probe substrate of CYP isoenzymes was used to evaluate the inhibitory properties of the compounds of the present invention on human liver microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4).
  • the test product will be prepared with DMSO into a 10mM stock solution. Add 178 ⁇ L of human liver microsomes and substrate mixture solution to the inhibitor-free control (NIC) and test sample wells of the reaction plate, and place on ice. Take 2 ⁇ L of the blank solvent and the working solution of the test product from the dilution plate and add them to the reaction plate (final concentration is 0.05-50 ⁇ M). Preheat the reaction plate in a 37 ⁇ 0.2°C water bath for 10 minutes. Use a liquid processing workstation to take 20 ⁇ L of the cofactor solution and add it to the reaction plate to start the reaction.
  • NIC inhibitor-free control
  • LC/MS/MS Liquid chromatography tandem mass spectrometry
  • LC-MS/MS Liquid chromatography-tandem mass spectrometry
  • the IC 50 value is calculated by a three-parameter or four-parameter inverse logarithmic equation. When the CYP percentage activity is greater than 50% under the highest concentration (50 ⁇ M) of the test substance, the IC 50 value is marked as ">50 ⁇ M".
  • x The concentration of the test product or positive control inhibitor.
  • IC 50 half inhibitory concentration.
  • the compound has little inhibitory effect on human liver microsomal cytochrome P450 isoenzymes, and has high drug interaction safety.
  • This experiment aims to study the pharmacokinetics of the compound of the present invention in the plasma of male CD-1 mice after intravenous injection and oral administration.
  • the animals were randomly divided into two groups with 2 males in each group.
  • the compound is formulated into the designated preparation, the intravenous injection preparation is prepared with 5% DMSO/95% (6% hydroxypropyl- ⁇ -cyclodextrin) to obtain a clear solution, and the oral preparation is prepared with 0.1% Tween80/0.5% HPMC aqueous solution to obtain a uniform mixture. Suspension.
  • WinNonlin TM Version 6.3.0 (Pharsight, Mountain View, CA) pharmacokinetic software was used to process the plasma drug concentration data of the compound in a non-compartmental model.
  • the peak concentration (C max ), peak time (T max ) and quantifiable end time can be obtained directly from the plasma concentration-time diagram.
  • the following pharmacokinetic parameters were calculated using the log-linear trapezoidal method: plasma clearance (CL), volume of distribution (Vd), elimination phase half-life (T 1/2 ), and the average residence time of the drug in the body from 0 o'clock to the end time. (MRT 0-last ), the average residence time of the drug in the body from 0 o’clock to infinite time (MRT 0-inf ), 0 o’clock to the end time point-area under the plasma concentration curve (AUC 0-last ), 0 o’clock to infinity Area under the time-plasma concentration curve (AUC 0-inf ) and bioavailability (F).
  • CL plasma clearance
  • Vd volume of distribution
  • T 1/2 elimination phase half-life
  • F bioavailability

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de bisamide de phényle. De façon spécifique, l'invention concerne un composé représenté par la formule (P) ou un sel pharmaceutiquement acceptable de celui-ci. (P)
PCT/CN2021/076912 2020-02-20 2021-02-19 Composé de bisamide de phényle WO2021164741A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010105349.7 2020-02-20
CN202010105349 2020-02-20

Publications (1)

Publication Number Publication Date
WO2021164741A1 true WO2021164741A1 (fr) 2021-08-26

Family

ID=77390451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/076912 WO2021164741A1 (fr) 2020-02-20 2021-02-19 Composé de bisamide de phényle

Country Status (1)

Country Link
WO (1) WO2021164741A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115210226A (zh) * 2020-02-20 2022-10-18 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683182A (zh) * 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
CN110036007A (zh) * 2016-09-29 2019-07-19 第一三共株式会社 吡啶化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105683182A (zh) * 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
CN110036007A (zh) * 2016-09-29 2019-07-19 第一三共株式会社 吡啶化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115210226A (zh) * 2020-02-20 2022-10-18 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
CN115210226B (zh) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物

Similar Documents

Publication Publication Date Title
JP7473642B2 (ja) Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用
WO2021110168A1 (fr) Composé spiro servant d'inhibiteur d'erk et son application
WO2022063190A1 (fr) Composé pyrazine thiobiphényle et son application
WO2022237797A1 (fr) Composés d'acide alkylcarboxylique et leur application
WO2021164742A1 (fr) Composés de quinoléine
WO2021164741A1 (fr) Composé de bisamide de phényle
WO2022002210A1 (fr) Composés deutérés de pyrimidopyrrolyle
US20220267321A1 (en) Azaindole pyrazole compounds as cdk9 inhibitors
CN113966335A (zh) 用于治疗癌症的egfr抑制剂
CN115894456A (zh) 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
WO2023001282A1 (fr) Dérivé de pyrimidine substitué par un hétérocycle
JP2807633B2 (ja) Ｎ−（ピリジニル）−ｉｈ−インドール−１−アミンを含有する強迫疾患治療剤
EP3868758B1 (fr) Dérivés de thiadiazole et leur utilisation en tant qu'inhibiteurs de gls1 dans le traitement du cancer
WO2021083319A1 (fr) Dérivés de thiophène en tant qu'inhibiteurs de xanthine oxydase et leur application
RU2811975C1 (ru) Конденсированное аза-гетероциклическое амидное соединение и его применение
RU2811975C9 (ru) Конденсированное аза-гетероциклическое амидное соединение и его применение
TWI836486B (zh) 二甲基取代的噻唑並內醯胺類化合物及其應用
WO2023237012A1 (fr) Composé deutéré de type acide carboxylique aromatique substitué bicyclique
US20230094146A1 (en) Deuterated thienopyridine compound
JP7198386B2 (ja) Ｒｅｔ阻害剤としての窒素含有スピロ環誘導体
WO2022194287A1 (fr) Composé de pyridinone bicyclique et son utilisation
MXPA06013484A (es) Metabolitos de (+)-(2s, 3s)-3-(2- metoxi-5- trifluorometoxibencilamino) -2-fenil- piperidina.
KR20240051146A (ko) 방향족 헤테로고리 화합물, 이를 함유한 약물 조성물 및 이의 응용
US20240002377A1 (en) Pyrrolopyridine compound and application thereof
WO2022206684A1 (fr) Série de composés de pyrazine contenant du sélénium et application associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21756471

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21756471

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21756471

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13/03/2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21756471

Country of ref document: EP

Kind code of ref document: A1